Related Concept Videos
You might also read
Related Articles
Articles linked to this work by shared authors, journal, and citation graph.
Delayed-Onset Cefepime Neurotoxicity in a Patient With Epilepsy and ESRD.
TIL cell therapy in HIV positive patient with metastatic melanoma: case report.
Rapid-access arrhythmia care as an integrated model: A RE-AIM guided systematic review.
Related Experiment Video
Updated: Jun 4, 2025

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
Recurrent Cardiac Tamponade from Multiple Myeloma While Receiving Teclistamab.
Alexander Hurtado1, Samuel T Luebbe1, Emma Kilbane1
1McGaw Medical Center of Northwestern University, Chicago, Illinois, USA.
Bispecific therapies offer new hope for multiple myeloma patients. However, this bispecific therapy may cause new or worsening pericardial disease, including cardiac tamponade and atrial fibrillation.
Area of Science:
- Cardiology
- Oncology
- Pharmacology
Background:
- Bispecific therapies represent a significant advancement in multiple myeloma treatment.
- Cardiovascular adverse events are a concern with novel cancer therapies.
More Related Videos
09:34Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
06:29Cardiac Magnetic Resonance for the Evaluation of Suspected Cardiac Thrombus: Conventional and Emerging Techniques
Published on: June 11, 2019